Systemic Blood Immune Cell Populations as Biomarkers for the Outcome of Immune Checkpoint Inhibitor Therapies

被引:26
作者
Hernandez, Carlos [1 ]
Arasanz, Hugo [1 ,2 ]
Chocarro, Luisa [1 ]
Bocanegra, Ana [1 ]
Zuazo, Miren [1 ]
Fernandez-Hinojal, Gonzalo [2 ]
Blanco, Ester [1 ]
Vera, Ruth [2 ]
Escors, David [1 ]
Kochan, Grazyna [1 ]
机构
[1] IdISNA, UPNA, Biomed Res Ctr Navarrabiomed, Oncoimmunol Grp, Irunlarrea 3, Pamplona 31008, Spain
[2] IdISNA, Complejo Hosp Navarra, Dept Oncol, Irunlarrea 3, Pamplona 31008, Spain
关键词
immunotherapy; immune checkpoint inhibitors; systemic blood subsets; CD4(+); CD8(+); MDSCs; MISMATCH REPAIR DEFICIENCY; MEMORY T-CELLS; PERIPHERAL-BLOOD; PD-1; BLOCKADE; CLINICAL-SIGNIFICANCE; IPILIMUMAB TREATMENT; PREDICTS RESPONSE; HYPERPROGRESSION; LYMPHOCYTES; INCREASES;
D O I
10.3390/ijms21072411
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The development of cancer immunotherapy in the last decade has followed a vertiginous rhythm. Nowadays, immune checkpoint inhibitors (ICI) which include anti-CTLA4, anti-PD-1 and anti-PD-L1 antibodies are in clinical use for the treatment of numerous cancers. However, approximately only a third of the patients benefit from ICI therapies. Many efforts have been made for the identification of biomarkers allowing patient stratification into potential responders and progressors before the start of ICI therapies or for monitoring responses during treatment. While much attention is centered on biomarkers from the tumor microenvironment, in many cases biopsies are not available. The identification of systemic immune cell subsets that correlate with responses could provide promising biomarkers. Some of them have been reported to influence the response to ICI therapies, such as proliferation and activation status of CD8 and CD4 T cells, the expression of immune checkpoints in peripheral blood cells and the relative numbers of immunosuppressive cells such as regulatory T cells and myeloid-derived suppressor cells. In addition, the profile of soluble factors in plasma samples could be associated to response or tumor progression. Here we will review the cellular subsets associated to response or progression in different studies and discuss their accuracy in diagnosis.
引用
收藏
页数:13
相关论文
共 63 条
[11]   Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab [J].
Gebhardt, Christoffer ;
Sevko, Alexandra ;
Jiang, Huanhuan ;
Lichtenberger, Ramtin ;
Reith, Maike ;
Tarnanidis, Kathrin ;
Holland-Letz, Tim ;
Umansky, Ludmila ;
Beckhove, Philipp ;
Sucker, Antje ;
Schadendorf, Dirk ;
Utikal, Jochen ;
Umansky, Viktor .
CLINICAL CANCER RESEARCH, 2015, 21 (24) :5453-5459
[12]   Immunosuppression mediated by myeloid-derived suppressor cells (MDSCs) during tumour progression [J].
Groth, Christopher ;
Hu, Xiaoying ;
Weber, Rebekka ;
Fleming, Viktor ;
Altevogt, Peter ;
Utikal, Jochen ;
Umansky, Viktor .
BRITISH JOURNAL OF CANCER, 2019, 120 (01) :16-25
[13]   Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer [J].
Hamanishi, Junzo ;
Mandai, Masaki ;
Iwasaki, Masashi ;
Okazaki, Taku ;
Tanaka, Yoshimasa ;
Yamaguchi, Ken ;
Higuchi, Toshihiro ;
Yagi, Haruhiko ;
Takakura, Kenji ;
Minato, Nagahiro ;
Honjo, Tasuku ;
Fujii, Shingo .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (09) :3360-3365
[14]   TCR Repertoire Diversity of Peripheral PD-1+CD8+ T Cells Predicts Clinical Outcomes after Immunotherapy in Patients with Non-Small Cell Lung Cancer [J].
Han, Jiefei ;
Duan, Jianchun ;
Bai, Hua ;
Wang, Yuqi ;
Wan, Rui ;
Wang, Xin ;
Chen, Si ;
Tian, Yanhua ;
Wang, Di ;
Fei, Kailun ;
Yao, Zhuoran ;
Wang, Shuhang ;
Lu, Zhimin ;
Wang, Zhijie ;
Wang, Jie .
CANCER IMMUNOLOGY RESEARCH, 2020, 8 (01) :146-154
[15]   A phase II study of five peptides combination with oxaliplatin-based chemotherapy as a first-line therapy for advanced colorectal cancer (FXV study) [J].
Hazama, Shoichi ;
Nakamura, Yusuke ;
Tanaka, Hiroaki ;
Hirakawa, Kosei ;
Tahara, Ko ;
Shimizu, Ryoichi ;
Ozasa, Hiroaki ;
Etoh, Ryuichi ;
Sugiura, Fumiaki ;
Okuno, Kiyotaka ;
Furuya, Takumi ;
Nishimura, Taku ;
Sakata, Koichiro ;
Yoshimatsu, Kazuhiko ;
Takenouchi, Hiroko ;
Tsunedomi, Ryouichi ;
Inoue, Yuka ;
Kanekiyo, Shinsuke ;
Shindo, Yoshitaro ;
Suzuki, Nobuaki ;
Yoshino, Shigefumi ;
Shinozaki, Hirokazu ;
Kamiya, Akira ;
Furukawa, Hiroyuki ;
Yamanaka, Takeharu ;
Fujita, Tomonobu ;
Kawakami, Yutaka ;
Oka, Masaaki .
JOURNAL OF TRANSLATIONAL MEDICINE, 2014, 12
[16]   T-cell invigoration to tumour burden ratio associated with anti-PD-1 response [J].
Huang, Alexander C. ;
Postow, Michael A. ;
Orlowski, Robert J. ;
Mick, Rosemarie ;
Bengsch, Bertram ;
Manne, Sasikanth ;
Xu, Wei ;
Harmon, Shannon ;
Giles, Josephine R. ;
Wenz, Brandon ;
Adamow, Matthew ;
Kuk, Deborah ;
Panageas, Katherine S. ;
Carrera, Cristina ;
Wong, Phillip ;
Quagliarello, Felix ;
Wubbenhorst, Bradley ;
D'Andrea, Kurt ;
Pauken, Kristen E. ;
Herati, Ramin S. ;
Staupe, Ryan P. ;
Schenkel, Jason M. ;
McGettigan, Suzanne ;
Kothari, Shawn ;
George, Sangeeth M. ;
Vonderheide, Robert H. ;
Amaravadi, Ravi K. ;
Karakousis, Giorgos C. . ;
Schuchter, Lynn M. ;
Xu, Xiaowei ;
Nathanson, Katherine L. ;
Wolchok, Jedd D. ;
Gangadhar, Tara C. ;
Wherry, E. John .
NATURE, 2017, 545 (7652) :60-+
[17]   T cell costimulatory receptor CD28 is a primary target for PD-1-mediated inhibition [J].
Hui, Enfu ;
Cheung, Jeanne ;
Zhu, Jing ;
Su, Xiaolei ;
Taylor, Marcus J. ;
Wallweber, Heidi A. ;
Sasmal, Dibyendu K. ;
Huang, Jun ;
Kim, Jeong M. ;
Mellman, Ira ;
Vale, Ronald D. .
SCIENCE, 2017, 355 (6332) :1428-+
[18]   Predictors of responses to immune checkpoint blockade in advanced melanoma [J].
Jacquelot, N. ;
Roberti, M. P. ;
Enot, D. P. ;
Rusakiewicz, S. ;
Ternes, N. ;
Jegou, S. ;
Woods, D. M. ;
Sodre, A. L. ;
Hansen, M. ;
Meirow, Y. ;
Sade-Feldman, M. ;
Burra, A. ;
Kwek, S. S. ;
Flament, C. ;
Messaoudene, M. ;
Duong, C. P. M. ;
Chen, L. ;
Kwon, B. S. ;
Anderson, A. C. ;
Kuchroo, V. K. ;
Weide, B. ;
Aubin, F. ;
Borg, C. ;
Dalle, S. ;
Beatrix, O. ;
Ayyoub, M. ;
Balme, B. ;
Tomasic, G. ;
Di Giacomo, A. M. ;
Maio, M. ;
Schadendorf, D. ;
Melero, I. ;
Dreno, B. ;
Khammari, A. ;
Dummer, R. ;
Levesque, M. ;
Koguchi, Y. ;
Fong, L. ;
Lotem, M. ;
Baniyash, M. ;
Schmidt, H. ;
Svane, I. M. ;
Kroemer, G. ;
Marabelle, A. ;
Michiels, S. ;
Cavalcanti, A. ;
Smyth, M. J. ;
Weber, S. ;
Eggermont, A. M. ;
Zitvogel, L. .
NATURE COMMUNICATIONS, 2017, 8
[19]   CD4+ T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy [J].
Kagamu, Hiroshi ;
Kitano, Shigehisa ;
Yamaguchi, Ou ;
Yoshimura, Kenichi ;
Horimoto, Katsuhisa ;
Kitazawa, Masashi ;
Fukui, Kazuhiko ;
Shiono, Ayako ;
Mouri, Atsuhito ;
Nishihara, Fuyumi ;
Miura, Yu ;
Hashimoto, Kosuke ;
Murayama, Yoshitake ;
Kaira, Kyoichi ;
Kobayashi, Kunihiko .
CANCER IMMUNOLOGY RESEARCH, 2020, 8 (03) :334-344
[20]   PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer [J].
Kamada, Takahiro ;
Togashi, Yosuke ;
Tay, Christopher ;
Ha, Danbee ;
Sasaki, Akinori ;
Nakamura, Yoshiaki ;
Sato, Eiichi ;
Fukuoka, Shota ;
Tada, Yasuko ;
Tanaka, Atsushi ;
Morikawa, Hiromasa ;
Kawazoe, Akihito ;
Kinoshita, Takahiro ;
Shitara, Kohei ;
Sakaguchi, Shimon ;
Nishikawa, Hiroyoshi .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2019, 116 (20) :9999-10008